RGSZ2 binds to the neural nitric oxide synthase PDZ domain to regulate mu-opioid receptor-mediated potentiation of the N-methyl-D-aspartate receptor-calmodulin-dependent protein kinase II pathway

Antioxidants and Redox Signaling

Volumn 15, Issue 4, 2011, Pages 873-887

  Garzón, Javier ^a,b   Rodríguez Muñoz, María ^b   Vicente Sánchez, Ana ^a   Bailón, Concha ^a,b   Martínez Murillo, Ricardo ^a,c   Sánchez Blázquez, Pilar ^a,b  

^a INSTITUTO CAJAL   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; MORPHINE SULFATE; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PROTEIN KINASE C; REGULATOR OF G PROTEIN SIGNALING Z2; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PDZ DOMAIN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SYNAPTOSOME;

AMINO ACID SEQUENCE; ANALGESICS, OPIOID; ANIMALS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; DRUG TOLERANCE; MALE; METABOLIC NETWORKS AND PATHWAYS; MICE; MOLECULAR SEQUENCE DATA; MORPHINE; NERVE TISSUE PROTEINS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; PDZ DOMAINS; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, OPIOID, MU; RGS PROTEINS; SIGNAL TRANSDUCTION;

MUS;

EID: 79960393240     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2010.3767     Document Type: Article

References (50)

1. Ai W, Gong J, and Yu L. MAP kinase activation by mu opioid receptor involves phosphatidylinositol 3-kinase but not the cAMP/PKA pathway. FEBS Lett 456: 196-200, 1999. (Pubitemid 29339068)
2. Ajit SK, Ramineni S, Edris W, Hunt RA, Hum WT, Hepler JR, and Young KH. RGSZ1 interacts with protein kinase C interacting protein PKCI-1 and modulates mu opioid receptor signaling. Cell Signal 19: 723-730, 2007. (Pubitemid 46275365)
3. Bleakman D, Alt A, and Nisenbaum ES. Glutamate receptors and pain. Semin Cell Dev Biol 17: 592-604, 2006. (Pubitemid 46389351)
4. Braithwaite SP, Paul S, Nairn AC, and Lombroso PJ. Synaptic plasticity: one STEP at a time. Trends Neurosci 29: 452-458, 2006. (Pubitemid 44118442)
5. Brenman JE, Chao DS, Gee SH, McGee AW, Craven SE, Santillano DR, Wu Z, Huang F, Xia H, Peters MF, Froehner SC, and Bredt DS. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell 84: 757-767, 1996. (Pubitemid 26094205)
6. Brenner GJ, Ji RR, Shaffer S, andWoolf CJ. Peripheral noxious stimulation induces phosphorylation of the NMDA receptor NR1 subunit at the PKC-dependent site, serine-896, in spinal cord dorsal horn neurons. Eur J Neurosci 20: 375-384, 2004. (Pubitemid 38969623)
7. Chakrabarti S, Liu NJ, and Gintzler AR. Reciprocal modulation of phospholipase Cb isoforms: adaptation to chronic morphine. Proc Natl Acad Sci USA 100: 13686-13691, 2003. (Pubitemid 37444800)
8. Chen L and Huang LY. Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by a l opioid. Neuron 7: 319-326, 1991.
9. Commons KG, van Bockstaele EJ, and Pfaff DW. Frequent colocalization of mu opioid and NMDA-type glutamate receptors at postsynaptic sites in periaqueductal gray neurons. J Comp Neurol 408: 549-559, 1999. (Pubitemid 29211181)
10. Daff S. NO synthase: structures and mechanisms. Nitric Oxide 23: 1-11, 2010.
11. Doyle GA, Furlong PJ, Schwebel CL, Smith GG, Lohoff FW, Buono RJ, Berrettini WH, and Ferraro TN. Fine mapping of a major QTL influencing morphine preference in C57BL/6 and DBA/2 mice using congenic strains. Neuropsychopharmacology 33: 2801-2809, 2008.
12. Dunkley PR, Jarvie PE, and Robinson PJ. A rapid Percoll gradient procedure for preparation of synaptosomes. Nat Protoc 3: 1718-1728, 2008.
13. Elliott K, Minami N, Kolesnikov YA, Pasternak GW, and Inturrisi CE. The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-Larginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain 56: 69-75, 1994.
14. Fisher K, Coderre TJ, and Hagen NA. Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage 20: 358-373, 2000.
15. Garzón J, Rodŕguez-Muñ oz M, López-Fando A, and Sánchez-Blázquez P. The RGSZ2 protein exists in a complex with mu-opioid receptors and regulates the desensitizing capacity of Gz proteins. Neuropsychopharmacology 30: 1632-1648, 2005. (Pubitemid 43086021)
16. Garzón J, Rodŕguez-Muñ oz M, and Sánchez- Blázquez P. Do pharmacological approaches that prevent opioid tolerance target different elements in the same regulatory machinery? Curr Drug Abuse Rev 1: 222-238, 2008.
17. Glass MJ, Vanyo L, Quimson L, and Pickel VM. Ultrastructural relationship between N-methyl-D-aspartate-NR1 receptor subunit and mu-opioid receptor in the mouse central nucleus of the amygdala. Neuroscience 163: 857-867, 2009.
18. Guang W, Wang H, Su T, Weinstein IB, and Wang JB. Role of mPKCI, a novel mu-opioid receptor interactive protein, in receptor desensitization, phosphorylation, and morphineinduced analgesia. Mol Pharmacol 66: 1285-1292, 2004. (Pubitemid 39411068)
19. Heo J and Campbell SL. Ras regulation by reactive oxygen and nitrogen species. Biochemistry 45: 2200-2210, 2006. (Pubitemid 43271319)
20. Inoue M, Mishina M, and Ueda H. Locus-specific rescue of GluRe1 NMDA receptors in mutant mice identifies the brain regions important for morphine tolerance and dependence. J Neurosci 23: 6529-6536, 2003. (Pubitemid 36909879)
21. Kissin I, Bright CA, and Bradley EL Jr. The effect of ketamine on opioid-induced acute tolerance: can it explain reduction of opioid consumption with ketamine-opioid analgesic combinations? Anesth Analg 91: 1483-1488, 2000.
22. Kolesnikov Y, Jain S, Wilson R, and Pasternak GW. Lack of morphine and enkephalin tolerance in 129/SvEv mice: evidence for a NMDA receptor defect. J Pharmacol Exp Ther 284: 455-459, 1998. (Pubitemid 28086628)
23. Kow LM, Commons KG, Ogawa S, and Pfaff DW. Potentiation of the excitatory action of NMDA in ventrolateral periaqueductal gray by the mu-opioid receptor agonist, DAMGO. Brain Res 935: 87-102, 2002. (Pubitemid 34327849)
24. Koyama S and Akaike N. Activation of mu-opioid receptor selectively potentiates NMDA-induced outward currents in rat locus coeruleus neurons. Neurosci Res 60: 22-28, 2008.
25. Leak TS, Mychaleckyj JC, Smith SG, Keene KL, Gordon CJ, Hicks PJ, Freedman BI, Bowden DW, and Sale MM. Evaluation of a SNP map of 6q24-27 confirms diabetic nephropathy loci and identifies novel associations in type 2 diabetes patients with nephropathy from an African-American population. Hum Genet 124: 63-71, 2008.
26. Lu WY, Xiong ZG, Lei S, Orser BA, Dudek E, Browning MD, and MacDonald JF. G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors. Nat Neurosci 2: 331-338, 1999. (Pubitemid 30491275)
27. LuginbuhlM,GerberA, Schnider TW, Petersen-Felix S, Arendt-Nielsen L, and CuratoloM.Modulation of remifentanil-induced analgesia, hyperalgesia, and tolerance by small-dose ketamine in humans. Anesth Analg 96: 726-732, 2003. (Pubitemid 36245560)
28. Mansour A, Khachaturian H, Lewis ME, Akil H, and Watson SJ. Anatomy of CNS opioid receptors. Trends Neurosci 11: 308-314, 1988.
29. Marek P, Ben-Eliyahu S, Vaccarino AL, and Liebeskind JC. Delayed application of MK-801 attenuates development of morphine tolerance in rats. Brain Res 558: 163-165, 1991.
30. Murthy KS and Makhlouf GM. Opioid mu, delta, and kappa receptor-induced activation of phospholipase C-beta 3 and inhibition of adenylyl cyclase is mediated by Gi2 and G(o) in smooth muscle. Mol Pharmacol 50: 870-877, 1996. (Pubitemid 26347707)
31. Narita M, Hashimoto K, Amano T, Narita M, Niikura K, Nakamura A, and Suzuki T. Post-synaptic action of morphine on glutamatergic neuronal transmission related to the descending antinociceptive pathway in the rat thalamus. J Neurochem 104: 469-478, 2008. (Pubitemid 350293886)
32. Pasternak GW, Kolesnikov YA, and Babey AM. Perspectives on the N-methyl-D-aspartate/nitric oxide cascade and opioid tolerance. Neuropsychopharmacology 13: 309-313, 1995. (Pubitemid 26008850)
33. Rameau GA, Tukey DS, Garcin-Hosfield ED, Titcombe RF, Misra C, Khatri L, Getzoff ED, and Ziff EB. Biphasic coupling of neuronal nitric oxide synthase phosphorylation to the NMDA receptor regulates AMPA receptor trafficking and neuronal cell death. J Neurosci 27: 3445-3455, 2007. (Pubitemid 46515122)
34. Rodŕguez-Muñ oz M, Bermúdez D, Sánchez- Blázquez P, and Garzón J. Sumoylated RGS-Rz proteins act as scaffolds for Mu-opioid receptors and G-protein complexes in mouse brain. Neuropsychopharmacology 32: 842-850, 2007. (Pubitemid 46426183)
35. Rodŕguez-Muñ oz M, de la Torre-Madrid E, Sánchez-Blázquez P, and Garzón J. Morphine induces endocytosis of neuronal mu-opioid receptors through the sustained transfer of Galpha subunits to RGSZ2 proteins. Mol Pain 3: 19, 2007.
36. Rodŕguez-Muñ oz M, de la Torre-Madrid E, Sánchez-Blázquez P, Wang JB, and Garzón J. NMDAR-nNOS generated zinc recruits PKCgamma to the HINT1-RGS17 complex bound to the C terminus of Mu-opioid receptors. Cell Signal 20: 1855-1864, 2008.
37. Rodŕguez-Muñ oz M, Sánchez-Blázquez P, Vicente-Sánchez A, Bailón C, Mart́n-Aznar B, and Garzón J. The histidine triad nucleotide-binding protein 1 supports mu-opioid receptor-glutamate NMDA receptor cross-regulation. Cell Mol Life Sci DOI 10.1007/s00018-010-0598-x, 2010.
38. Sánchez-Blázquez P, Rodŕguez-Muñ oz M, de la Torre-Madrid E, and Garzón J. Brain-specific Gaz interacts with Src tyrosine kinase to regulate Mu-opioid receptor-NMDAR signaling pathway. Cell Signal 21: 1444-1454, 2009.
39. Sánchez-Blázquez P, Rodŕguez-Muñ oz M, and Garzón J. Mu-opioid receptors transiently activate the Akt-nNOS pathway to produce sustained potentiation of PKC-mediated NMDAR-CaMKII signaling. PLoS ONE 5: e11278, 2010.
40. Sánchez-Blázquez P, Rodŕguez-Muñ oz M, Montero C, de la Torre-Madrid E, and Garzón J. Calcium/calmodulindependent protein kinase II supports morphine antinociceptive tolerance by phosphorylation of glycosylated phosducin-like protein. Neuropharmacology 54: 319-330, 2008.
41. Saper CB and Sawchenko PE. Magic peptides, magic antibodies: guidelines for appropriate controls for immunohistochemistry. J Comp Neurol 465: 161-163, 2003. (Pubitemid 37100126)
42. Schulz S, Mayer D, Pfeiffer M, Stumm R, Koch T, and Hö llt V. Morphine induces terminal micro-opioid receptor desensitization by sustained phosphorylation of serine-375. EMBO J 23: 3282-3289, 2004. (Pubitemid 39209152)
43. Serrano J, Fernandez AP, Sánchez J, Rodrigo J, and Mart́nez A. Adrenomedullin expression is up-regulated by acute hypobaric hypoxia in the cerebral cortex of the adult rat. Brain Pathol 18: 434-442, 2008. (Pubitemid 351782852)
44. Sierra DA, Gilbert DJ, Householder D, Grishin NV, Yu K, Ukidwe P, Barker SA, He W, Wensel TG, Otero G, Brown G, Copeland NG, Jenkins NA, and Wilkie TM. Evolution of the regulators of G-protein signaling multigene family in mouse and human. Genomics 79: 177-185, 2002.
45. Tochio H, Zhang Q, Mandal P, Li M, and Zhang M. Solution structure of the extended neuronal nitric oxide synthase PDZ domain complexed with an associated peptide. Nat Struct Biol 6: 417-421, 1999. (Pubitemid 29218008)
46. Trujillo KA and Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251: 85-87, 1991. (Pubitemid 21916858)
47. Yaksh TL, Yeung JC, and Rudy TA. Systematic examination in the rat of brain sites sensitive to the direct application of morphine: observation of differential effects within the periaqueductal gray. Brain Res 114: 83-103, 1976.
48. Yun HY, Gonzalez-Zulueta M, Dawson VL, and Dawson TM. Nitric oxide mediates N-methyl-D-aspartate receptorinduced activation of p21ras. Proc Natl Acad Sci USA 95: 5773-5778, 1998.
49. Zhou L and Zhu DY. Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide 20: 223-230, 2009.
50. Zhu JJ, Qin Y, Zhao M, Van AL, and Malinow R. Ras and Rap control AMPA receptor trafficking during synaptic plasticity. Cell 110: 443-455, 2002. (Pubitemid 35232288)